Phase II study of metastatic melanoma using lymphodepleting conditioning followed by infusion of anti-gp 100:154-162 TCR-gene engineered lymphocytes.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Gp100-specific T lymphocyte therapy (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine; Interleukin-2
- Indications Malignant melanoma
- Focus Therapeutic Use
- 15 Jan 2013 Biomarkers information updated
- 14 Jan 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 23 Aug 2011 Planned end date changed from 1 Jul 2011 to 1 Jul 2012 as reported by ClinicalTrials.gov.